MBX Biosciences, Inc. Common Stock
Price Action
Technical Summary
EMERGING TRENDMBX Biosciences, Inc. Common Stock is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 17% provides fundamental context to the price action. Investors should exercise caution due to high volatility (90% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $31.90 | +8.81% | ABOVE |
| 50 SMA | $30.79 | +12.74% | ABOVE |
| 100 SMA | $33.00 | +5.18% | ABOVE |
| 150 SMA | $29.59 | +17.30% | ABOVE |
| 200 SMA | $25.62 | +35.49% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MBX in an uptrend right now?
MBX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is MBX overbought or oversold?
MBX's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is MBX outperforming the market?
MBX has a Relative Strength (RS) Rating of 84 out of 99. Yes, MBX is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is MBX in its 52-week range?
MBX is trading at $34.71, which is 77% of its 52-week high ($44.89) and 71% above its 52-week low ($9.43).
How volatile is MBX?
MBX has a Beta of 1.33 and 52-week volatility of 90%. It's more volatile than the S&P 500 - expect bigger swings.